Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease
worldwide. With no Food and Drug Administration approved drugs, current treatment options …

Nonalcoholic fatty liver disease (NAFLD) is a heterogeneous group of liver diseases
characterized by the accumulation of fat in the liver. The heterogeneity of NAFLD is reflected …

The lack of registered drugs for nonalcoholic fatty liver disease (NAFLD) is partly due to the
paucity of human-relevant models for target discovery and compound screening. Here we …

Nonalcoholic fatty liver disease (NAFLD) is a main hepatic manifestation of metabolic
syndrome. It represents a wide spectrum of histopathological abnormalities ranging from …

Cell death represents a basic biological paradigm that governs outcomes and long-term
sequelae in almost every hepatic disease condition. Acute liver failure is characterized by …

Innate immune activation contributes to the transition from nonalcoholic fatty liver to
nonalcoholic steatohepatitis (NASH). Stimulator of IFN genes (STING, also referred to …

Fibrosis is a pathological feature of most chronic inflammatory diseases. Fibrosis, or
scarring, is defined by the accumulation of excess extracellular matrix components. If highly …

Bidirectional somatic cell–oocyte signaling is essential to create a changing intrafollicular
microenvironment that controls primordial follicle growth into a cohort of growing follicles …

Inflammation can be either beneficial or detrimental to the liver, depending on multiple
factors. Mild (ie, limited in intensity and destined to resolve) inflammatory responses have …

Based on the assumption that characterizing the history of a disease will help in improving
practice while offering a clue to research, this article aims at reviewing the history of …